News | Hemodynamic Support Devices | January 25, 2018

Circulatory Support Devices Study Shows Heart Donor Shortage, Improved Survival With VADS

This research report provides an in-depth analysis of the market in terms of revenue and emerging market trends.

Technavio Market Study Shows Donor Shortage and Improved Survival Rate

January 25, 2018 – According to the latest market study released by Technavio, the global circulatory support devices market is expected to grow at a compounded annual growth rate (CAGR) of more than 11 percent during the forecast period.

This research report titled “Global Circulatory Support Devices Market 2017-2021” provides an in-depth analysis of the market in terms of revenue and emerging market trends. This report also includes an up to date analysis and forecasts for various market segments and all geographical regions.

The market research analysis categorizes the global circulatory support devices market into three major product segments:

 

Global VAD market

The global VAD market is growing at a significant rate owing to its cost-effectiveness when compared to heart transplantation. Shortage of donors and improved survival rate are the major factors driving the demand for these supporting devices. VAD will provide aid to the heart but not completely replace heart activities. Also, the advances in technology in terms of design are playing a key role in higher adoption of VAD in developed countries. The growing number of patients with congestive heart failure (IV stage) is another main factor driving the sales of VADs in the global circulatory support devices market. Moreover, advances in technology have led to the development of new generation LVADs, which are small, less noisy, and durable with enhanced power sources.

 

Global ECMO market

The global ECMO market is expected to grow at a moderate rate owing to the growing incidence of cardiovascular disorders, respiratory disorders, and the growing geriatric population. In addition, the outspread application of ECMO is driving the demand through various application segments such as cardiac, respiratory, and extracorporeal cardiopulmonary resuscitation (ECPR).

“In addition, a significant rise in ECMO centers, rising awareness through conferences and training programs, and the advances in technology are significant factors driving the demand for ECMO supporting devices during the forecast period. Also, the growing older population in APAC and a significant number of people with cardiopulmonary diseases in developing nations such as China and India are expected to provide the potential growth opportunity for ECMO devices,” said Barath Palada, a lead analyst at Technavio for cardiovascular devices research.

 

Global TAH market

The global TAH market is growing at a faster rate compared with other circulatory assist devices globally. Europe is the leading revenue contributor to the global TAH market, followed by the Americas and APAC. Europe dominates the market, as the device got European Medicines Agency (EMA) approval before the U.S. FDA approval and had early adoption advantage for the end-users.

The market for TAH is expected to benefit from the fact that it is the only option, which can provide a permanent solution in the absence of a donor's heart. The TAH is gaining popularity among critically ill patients, who are in life-threatening condition due to extreme malfunction of their heart. The TAH will enhance the life expectancy of people with end-stage heart failure and extend the life expectancy over months compared with the other circulatory support devices.

The top vendors highlighted by Technavio’s market research analysts in this report are:

  • Medtronic
  • St. Jude Medical
  • Abiomed
  • ReliantHeart
  • Berlin Heart

For more information: www.technavio.com


Related Content

News | Hemodynamic Support Devices

October 23, 2023 — Supira Medical, Inc., a Shifamed portfolio company, announced that the company's percutaneous ...

Home October 23, 2023
Home
News | Hemodynamic Support Devices

November 1, 2022 — Abiomed announced that Impella RP Flex with SmartAssist has received U.S. Food and Drug ...

Home November 01, 2022
Home
News | Hemodynamic Support Devices

September 17, 2022 — Results of a new per-protocol analysis of the ST-segment Elevation Myocardial Infarction Door-To ...

Home September 17, 2022
Home
News | Hemodynamic Support Devices

November 12, 2020 — Abiomed recently announced new PROTECT III study data that demonstrates reduced rates of MACCE ...

Home November 12, 2020
Home
Videos | Hemodynamic Support Devices

Chuck Simonton, M.D., chief medical officer at Abiomed, discusses some of the new technologies and clinical trials the ...

Home October 20, 2020
Home
News | Hemodynamic Support Devices

October 16, 2020 — The Restore EF Study demonstrates the use of contemporary best practices, including attempting a more ...

Home October 16, 2020
Home
News | Hemodynamic Support Devices

July 16, 2020 – The U.S. Food and Drug Administration (FDA) approved one-way digital data streaming during patient ...

Home July 16, 2020
Home
News | Hemodynamic Support Devices

June 5, 2020 — Abiomed announced the U.S. Food and Drug Administration (FDA) has approved the company's investigational ...

Home June 05, 2020
Home
Videos | Hemodynamic Support Devices

This is a quick animation demonstrating how the new 9 French Abiomed Impella ECP expands to approximately 18 French and ...

Home June 05, 2020
Home
Subscribe Now